Aurinia Pharmaceuticals (AUPH) FCF Margin (2020 - 2026)

Aurinia Pharmaceuticals (AUPH) has 7 years of FCF Margin data on file, last reported at 41.85% in Q1 2026.

• Quarterly FCF Margin rose 3980.0% year-over-year to 41.85% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 56.19% (up 3019.0% YoY) and the FY2025 annual result came in at 48.18%, up 2929.0% from the prior year.
• FCF Margin eased to 41.85% in Q1 2026, from 59.22% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 64.26% in Q2 2025 to a low of 216.53% in Q1 2022.
• A 5-year average of 6.16% and a median of 25.32% in 2024 frame the typical range for FCF Margin.
• Annual changes were most pronounced in 2022 — FCF Margin jumped 561629 bps — and 2023, when it slumped 340 bps.
• Tracing AUPH's FCF Margin over 5 years: stood at 36.03% in 2022, then declined by 9 bps to 32.63% in 2023, then jumped by 54 bps to 50.37% in 2024, then increased by 18 bps to 59.22% in 2025, then declined by 29 bps to 41.85% in 2026.
• The last three FCF Margin figures came in at 41.85% (Q1 2026), 59.22% (Q4 2025), and 60.5% (Q3 2025), per Business Quant data.